RespireRx Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RSPI RespireRx Pharmaceuticals Inc
CCI Crown Castle International Corp
DOC Physicians Realty Trust
CYDVF Cypress Development Corp
KEYS Keysight Technologies Inc
HBAN Huntington Bancshares Inc
MMP Magellan Midstream Partners LP
VTI Vanguard Total Stock Market Index Fund ETF Shares
SKX Skechers USA Inc
RMGCW RMG Acquisition Equity III Warrant Exp 08 Feb 2026 *W EXP 02/08/2026
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

RespireRx Pharmaceuticals Inc. is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. Its pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system’s endogenous cannabinoid receptors. Its neuromodulators platform consists of two programs: its AMPAkines program, which includes compounds that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors to promote neuronal function and GABAkines program, including compounds that are PAMs of GABAA receptors.

The symbol you entered, COR, changed to RSPI.

Closing Price
$0.015
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
76,243
0

There is no peer information for RSPI.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.